ARIAD Pharmaceuticals
 |
|
| Subsidiary | |
| Traded as | NASDAQ: ARIA |
| Industry | Pharmaceuticals, biotechnology |
| Fate | Merged with Takeda Pharmaceuticals |
| Founded | 1991 |
| Defunct | 2017 |
| Headquarters | Cambridge, MA, United States |
|
Key people
|
Harvey Berger (CEO) Alex Denner, Chairman of the Board Harvey Berger, retired (as of December 2015) Chairman & CEO Timothy P. Clackson, President of Research and Development and Chief Scientific Officer |
| Products |
Ridaforolimus (Under development) Ponatinib (FDA approved, trade name Iclusig) Brigatinib (Under development) |
| Revenue |
 US$178.98M (FY 2010)
|
|
US$104.90M (FY 2010)
|
|
|
US$85.25M (FY 2010)
|
|
| Total assets |
 US$50.4M (FY 2010)
|
|
Number of employees
|
125 (2011) |
| Website | www.ariad.com |
ARIAD Pharmaceuticals, Inc. was an American oncology company founded in 1991 and headquartered in Cambridge, Massachusetts. On February 16th, 2017, Takeda announced it had completed its acquisition of Ariad.
On December 14, 2012 the FDA approved Ariad Pharmaceutical's leukemia drug Iclusig for patients with all forms of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or unable to tolerate other tyrosine kinase therapies on the market. The drug was temporarily withdrawn from the market in November 2013 "because of the risk of life-threatening blood clots and severe narrowing of blood vessels". This suspension was partially lifted on December 20, 2013 with ponatinib being issued revised prescribing information, a new "black box warning" and a "Risk Evaluation and Mitigation Strategy" in place to better evaluate the risks and benefits of using the drug.
Ariad also has brigatinib, a lung cancer drug which has completed its registration trial in ALK fusion driven non-small cell lung cancer as of June 2016.
In January 2017, Takeda announced it would acquire Ariad for $5.2 billion, expanding the company's oncology and hematology divisions. The acquisition was completed on February 16th, 2017.
Ariad is engaged in the discovery, development, and commercialization of medicines for cancer patients. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States and Europe. Various investigator-sponsored trials are ongoing in several indications, including first line and second line CML, acute lymphoblastic leukemia (BCR-ABL), acute myeloid leukemia (FLT3 inhibitor), non-small cell lung cancer (RET, FGFR), advanced biliary cancer With FGFR2 fusions and other cancers with activating mutations involving the following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, and KIT.
...
Wikipedia